An observational study in Cardiovascular Disease, sponsored by Kumamoto University. Completed at 1 site in Japan. Open to participants aged 30 Years to 90 Years. Per ClinicalTrials.gov, last updated 2017-08-24.
Sponsored by Kumamoto University · Observational
The investigators test the additional clinical value of the physiological assessment of endothelial function to the morphological assessment of coronary complexity and classical risk score in predicting cardiovascular events.
The investigators enroll consecutive, stable high risk patients for cardiovascular events. The reactive hyperemia peripheral arterial tonometry index (RHI) was measured before coronary angiography and coronary lesions were assessed angiographically by SYNTAX Scoring system. The investigators all subjects and examined the occurrence of cardiovascular events (CV death, non-fatal myocardial infarction and ischemic stroke, unstable angina pectoris, hospitalization for HF, coronary revascularization, or non-fatal aortic and peripheral vascular disease).
4,902 studies on the registry are indexed under Cardiovascular Diseases; 920 are open to participants now.
This study's enrollment of 1,000 is above the median of 573 across 1,483 observational studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Kumamoto University is the lead sponsor of 23 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Kumamoto University Hospital and Yokohama City University Medical Center
Exclusion Criteria:
Cardiovascular event
Cardiovascular event consists of cardiovascular death, myocardial infarction, unstable angina, ischemic stroke, coronary revascularization, hospitalization for heart failure, aortic disease and peripheral arterial disease.
Time frame: Outcome is assessed 1 to 4 years after entry
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kumamoto University